18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer

Kazuki Takada, Gouji Toyokawa, Yasuto Yoneshima, Kentaro Tanaka, Isamu Okamoto, Mototsugu Shimokawa, Sho Wakasu, Akira Haro, Atsushi Osoegawa, Tetsuzo Tagawa, Yoshinao Oda, Yoichi Nakanishi, Masaki Mori

研究成果: ジャーナルへの寄稿記事

抄録

To examine the association between 18F-fluorodeoxyglucose (18F-FDG) uptake in positron emission tomography/computed tomography (PET/CT) and the response to anti-programmed cell death-1 (PD-1) monoclonal antibody therapy in non-small cell lung cancer (NSCLC) patients, 89 patients with advanced or recurrent NSCLC were retrospectively analysed. Maximum standardized uptake value (SUVmax) in 18F-FDG PET/CT and the response to anti-PD-1 antibodies were recorded. A cut-off value of SUVmax was determined by receiver operating characteristic curve analysis for patient stratification. Among the 89 patients evaluated, 24 were classified as responders (all partial response), and 65 as non-responders. The average SUVmax of the responders was 15.60 (range, 6.44–51.10), which was significantly higher than that of the non-responders (11.61; range, 2.13–32.75; P = 0.0168, Student’s t-test). The cut-off SUVmax value selected for stratification was 11.16 (sensitivity and specificity, 0.792 and 0.585, respectively). The response rate of patients with SUVmax value ≥ 11.16 (41.3% [19/46]) was significantly higher than that of patients with SUVmax < 11.16 (11.6% [5/43], P = 0.0012, Chi-squared test). The SUVmax in 18F-FDG PET/CT is a potential predictive marker of response to anti-PD-1 antibody therapy in NSCLC patients. Further prospective studies of large populations are necessary to validate these results.

元の言語英語
記事番号13362
ジャーナルScientific reports
9
発行部数1
DOI
出版物ステータス出版済み - 12 1 2019

Fingerprint

Fluorodeoxyglucose F18
Non-Small Cell Lung Carcinoma
Cell Death
Biomarkers
Antibodies
Therapeutics
Positron Emission Tomography Computed Tomography
ROC Curve
Monoclonal Antibodies
Prospective Studies
Students
Sensitivity and Specificity
Population

All Science Journal Classification (ASJC) codes

  • General

これを引用

18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. / Takada, Kazuki; Toyokawa, Gouji; Yoneshima, Yasuto; Tanaka, Kentaro; Okamoto, Isamu; Shimokawa, Mototsugu; Wakasu, Sho; Haro, Akira; Osoegawa, Atsushi; Tagawa, Tetsuzo; Oda, Yoshinao; Nakanishi, Yoichi; Mori, Masaki.

:: Scientific reports, 巻 9, 番号 1, 13362, 01.12.2019.

研究成果: ジャーナルへの寄稿記事

Takada, Kazuki ; Toyokawa, Gouji ; Yoneshima, Yasuto ; Tanaka, Kentaro ; Okamoto, Isamu ; Shimokawa, Mototsugu ; Wakasu, Sho ; Haro, Akira ; Osoegawa, Atsushi ; Tagawa, Tetsuzo ; Oda, Yoshinao ; Nakanishi, Yoichi ; Mori, Masaki. / 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. :: Scientific reports. 2019 ; 巻 9, 番号 1.
@article{0b08ecf6bb7549ef85eaac67c2ac83b7,
title = "18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer",
abstract = "To examine the association between 18F-fluorodeoxyglucose (18F-FDG) uptake in positron emission tomography/computed tomography (PET/CT) and the response to anti-programmed cell death-1 (PD-1) monoclonal antibody therapy in non-small cell lung cancer (NSCLC) patients, 89 patients with advanced or recurrent NSCLC were retrospectively analysed. Maximum standardized uptake value (SUVmax) in 18F-FDG PET/CT and the response to anti-PD-1 antibodies were recorded. A cut-off value of SUVmax was determined by receiver operating characteristic curve analysis for patient stratification. Among the 89 patients evaluated, 24 were classified as responders (all partial response), and 65 as non-responders. The average SUVmax of the responders was 15.60 (range, 6.44–51.10), which was significantly higher than that of the non-responders (11.61; range, 2.13–32.75; P = 0.0168, Student’s t-test). The cut-off SUVmax value selected for stratification was 11.16 (sensitivity and specificity, 0.792 and 0.585, respectively). The response rate of patients with SUVmax value ≥ 11.16 (41.3{\%} [19/46]) was significantly higher than that of patients with SUVmax < 11.16 (11.6{\%} [5/43], P = 0.0012, Chi-squared test). The SUVmax in 18F-FDG PET/CT is a potential predictive marker of response to anti-PD-1 antibody therapy in NSCLC patients. Further prospective studies of large populations are necessary to validate these results.",
author = "Kazuki Takada and Gouji Toyokawa and Yasuto Yoneshima and Kentaro Tanaka and Isamu Okamoto and Mototsugu Shimokawa and Sho Wakasu and Akira Haro and Atsushi Osoegawa and Tetsuzo Tagawa and Yoshinao Oda and Yoichi Nakanishi and Masaki Mori",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-50079-2",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer

AU - Takada, Kazuki

AU - Toyokawa, Gouji

AU - Yoneshima, Yasuto

AU - Tanaka, Kentaro

AU - Okamoto, Isamu

AU - Shimokawa, Mototsugu

AU - Wakasu, Sho

AU - Haro, Akira

AU - Osoegawa, Atsushi

AU - Tagawa, Tetsuzo

AU - Oda, Yoshinao

AU - Nakanishi, Yoichi

AU - Mori, Masaki

PY - 2019/12/1

Y1 - 2019/12/1

N2 - To examine the association between 18F-fluorodeoxyglucose (18F-FDG) uptake in positron emission tomography/computed tomography (PET/CT) and the response to anti-programmed cell death-1 (PD-1) monoclonal antibody therapy in non-small cell lung cancer (NSCLC) patients, 89 patients with advanced or recurrent NSCLC were retrospectively analysed. Maximum standardized uptake value (SUVmax) in 18F-FDG PET/CT and the response to anti-PD-1 antibodies were recorded. A cut-off value of SUVmax was determined by receiver operating characteristic curve analysis for patient stratification. Among the 89 patients evaluated, 24 were classified as responders (all partial response), and 65 as non-responders. The average SUVmax of the responders was 15.60 (range, 6.44–51.10), which was significantly higher than that of the non-responders (11.61; range, 2.13–32.75; P = 0.0168, Student’s t-test). The cut-off SUVmax value selected for stratification was 11.16 (sensitivity and specificity, 0.792 and 0.585, respectively). The response rate of patients with SUVmax value ≥ 11.16 (41.3% [19/46]) was significantly higher than that of patients with SUVmax < 11.16 (11.6% [5/43], P = 0.0012, Chi-squared test). The SUVmax in 18F-FDG PET/CT is a potential predictive marker of response to anti-PD-1 antibody therapy in NSCLC patients. Further prospective studies of large populations are necessary to validate these results.

AB - To examine the association between 18F-fluorodeoxyglucose (18F-FDG) uptake in positron emission tomography/computed tomography (PET/CT) and the response to anti-programmed cell death-1 (PD-1) monoclonal antibody therapy in non-small cell lung cancer (NSCLC) patients, 89 patients with advanced or recurrent NSCLC were retrospectively analysed. Maximum standardized uptake value (SUVmax) in 18F-FDG PET/CT and the response to anti-PD-1 antibodies were recorded. A cut-off value of SUVmax was determined by receiver operating characteristic curve analysis for patient stratification. Among the 89 patients evaluated, 24 were classified as responders (all partial response), and 65 as non-responders. The average SUVmax of the responders was 15.60 (range, 6.44–51.10), which was significantly higher than that of the non-responders (11.61; range, 2.13–32.75; P = 0.0168, Student’s t-test). The cut-off SUVmax value selected for stratification was 11.16 (sensitivity and specificity, 0.792 and 0.585, respectively). The response rate of patients with SUVmax value ≥ 11.16 (41.3% [19/46]) was significantly higher than that of patients with SUVmax < 11.16 (11.6% [5/43], P = 0.0012, Chi-squared test). The SUVmax in 18F-FDG PET/CT is a potential predictive marker of response to anti-PD-1 antibody therapy in NSCLC patients. Further prospective studies of large populations are necessary to validate these results.

UR - http://www.scopus.com/inward/record.url?scp=85072267654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072267654&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-50079-2

DO - 10.1038/s41598-019-50079-2

M3 - Article

C2 - 31527660

AN - SCOPUS:85072267654

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 13362

ER -